Search

Search Constraints

You searched for: Author/Creator Sacher, Adrian

Search Results

2. ALK-rearranged lung adenocarcinoma transformation into high-grade large cell neuroendocrine carcinoma: Clinical and molecular description of two cases. (August 2020)

3. BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer. (August 2020)

4. Development of the Functional Assessment of Cancer Therapy–Immune Checkpoint Modulator (FACT‐ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs. Issue 7 (8th January 2020)

5. 379 Initial safety, efficacy, and product attributes from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating an affinity optimized TCR targeting MAGE-A4 and a CD8α co-receptor. (9th November 2020)

6. 379 Initial safety, efficacy, and product attributes from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating an affinity optimized TCR targeting MAGE-A4 and a CD8α co-receptor. (9th November 2020)

8. Chemical Genetics Screen Identifies COPB2 Tool Compounds That Alters ER Stress Response and Induces RTK Dysregulation in Lung Cancer Cells. Issue 23 (19th November 2021)

9. Treatment patterns and outcomes in early-stage ALK-rearranged non-small cell lung cancer. (April 2022)

10. The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer. (November 2021)